Publications by authors named "M Maticic"
Background: With the advent of direct acting antivirals (DAAs) the World Health Organisation (WHO) adopted global strategy to eliminate hepatitis C virus (HCV) infection by 2030. In Europe, people who inject drugs (PWID) account for the majority of new cases, however testing and treatment remain suboptimal. The aim was to monitor progress in HCV policy and cascade-of-care for PWID, led by the civil society organisations (CSO) that provide harm reduction services for PWID across Europe.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to estimate the prevalence of chronic Hepatitis C Virus (cHCV) infections in EU/EEA countries for the year 2019, using a method called multi-parameter evidence synthesis (MPES) to analyze data from various sources.
- - In 29 out of 30 EU/EEA countries, the overall cHCV prevalence was found to be 0.50%, with notably higher rates in the eastern EU/EEA (0.88%), and over a third of cases were linked to people who inject drugs (PWID).
- - The findings indicate that while cHCV prevalence is generally low, targeted efforts are needed, particularly in eastern regions and among PWID, to
Monitoring progress towards elimination of hepatitis B and C in the EU/EEA.
PLOS Glob Public Health
August 2022
This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from the EU/EEA countries via an online survey.
View Article and Find Full Text PDF